Vice President, Translational Medicine

Company: At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Our novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, we are rigorously advancing our mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. At Annexon, you’ll be part of a team committed to making an impact together. For more information on Annexon and our pipeline, check out our site Annexon Biosciences & Annexon Pipeline . We trade on Nasdaq under the ticker symbol ANNX and are headquartered in Brisbane, CA. We're seeking exceptional talent from all backgrounds to fuel our growth. At Annexon, we're building a diverse, equitable, and inclusive workplace. We value unique perspectives and unconventional paths. If you're the best candidate for the job, even if you don't perfectly fit the traditional mold, we encourage you to apply. Learn more about our commitment to diversity, equity, inclusion, and our company culture ! Position: We are seeking an accomplished, experienced, and creative development leader to join our team as Vice President, Translational Medicine . The VP, Translational Medicine will play a critical role in shaping and executing Annexon’s translational strategy across our portfolio of classical complement biology programs spanning diseases of the body, brain, and eye. This position will serve as a key scientific and strategic partner to Clinical Development, Discovery, Regulatory, Clinical Operations, and Medical Affairs—ensuring that mechanistic hypotheses are translated into human biology evidence, biomarker strategies, and data-driven decision-making to accelerate development. The VP, Translational Medicine will lead translational planning and execution for flagship and next-wave programs, including tanruprubart (ANX005) in Guillain-Barré syndrome (GBS), vonaprument (ANX007) in dry AMD with geographic atrophy (GA), neurodegenerative programs including Huntington’s disease and ALS, and acute indications such as traumatic brain injury (TBI) and myasthenic crisis. This role requires a seasoned leader with deep expertise in translational medicine, biomarker strategy, assay development, bioinformatics, statistics, and clinical development—ideally with strong domain experience in neurology, ophthalmology, and/or immunology/rheumatology—and a track record of building and leading high-performing translational organizations within pharma or biopharma. Like all Annexon leaders, the VP, Translational Medicine incumbent will have a deep-rooted commitment to serving patients and a passion for transforming the lives of people with serious diseases and their families. Responsibilities include: Translational Medicine Leadership & Strategy: Serve as the Translational Medicine Lead across Annexon programs, setting an integrated, portfolio-level strategy that links mechanism of action to clinical outcomes in complement-mediated diseases of the body, brain, and eye Partner with Program Team Leaders, Clinical Development leads, and program teams to define translational hypotheses, proof-of-mechanism and proof-of-concept strategies, and key decision criteria for each stage of development Provide leadership for translational prioritization, resource planning, and execution in a fast-paced, dynamic environment consistent with a lean biotech operating model Build and lead a high-performing Translational Medicine organization spanning biomarker science, translational bioinformatics/omics, assay development/operations, and sample/d…